Summary of Key Points Core Viewpoint - The Hong Kong biotechnology sector experienced a significant decline, with most stocks falling sharply, indicating a bearish trend in the market [1]. Company Performance - **Gilead Sciences (歌礼制药-B)**: Decreased by 15.06%, latest price at 15.510, market cap at 14.946 billion [2]. - **Yunkang Group (云康集团)**: Fell by 14.18%, latest price at 2.300, market cap at 1.429 billion [2]. - **PAG Pharmaceuticals (派格生物医药-B)**: Dropped by 9.15%, latest price at 31.760, market cap at 12.258 billion [2]. - **Tengsheng Boao (腾盛博药-B)**: Declined by 8.30%, latest price at 2.210, market cap at 1.590 billion [2]. - **China Antibody (中国抗体-B)**: Decreased by 7.49%, latest price at 3.210, market cap at 4.371 billion [2]. - **Jiahua Biotech (嘉和生物-B)**: Fell by 7.08%, latest price at 4.460, market cap at 2.347 billion [2]. - **Sillod Pharmaceuticals (思路迪医药股份)**: Dropped by 6.06%, latest price at 7.910, market cap at 2.042 billion [2]. - **Tiger Med (泰格医药)**: Decreased by 5.73%, latest price at 54.250, market cap at 46.711 billion [2]. - **Kangji Medical (加科思-B)**: Fell by 5.69%, latest price at 8.120, market cap at 6.404 billion [2]. - **WuXi AppTec (药明巨诺-B)**: Dropped by 5.14%, latest price at 5.720, market cap at 2.382 billion [2]. - **Three Leaf Clover Biotech (三叶草生物-B)**: Decreased by 5.13%, latest price at 0.740, market cap at 0.960 billion [2]. - **Yiming Oncology (宜明昂科-B)**: Fell by 4.76%, latest price at 12.810, market cap at 5.218 billion [2]. - **Junshi Biosciences (君实生物)**: Decreased by 4.69%, latest price at 34.540, market cap at 35.462 billion [2]. - **Zhonghui Biotech (中慧生物-B)**: Fell by 4.39%, latest price at 51.150, market cap at 20.125 billion [2]. - **Zhaoyan New Drug (昭衍新药)**: Decreased by 4.38%, latest price at 23.140, market cap at 17.343 billion [2].

宜明昂科-B(01541)公布，IMC-003/IMM72第一期临床试验的首名患者已成功给药，标志着集团IMC- 003/IMM72临床研究的重大里程碑，并为促进随后临床试验奠定稳健基础。 据悉，IMC-003/IMM72为通过基因改造的新一代启动素受体IIA-Fc型(ActRIIA-Fc)融合蛋白，具有更高 的活性及品质。该集团拥有IMC-003/IMM72的全球知识产权以及开发及商业化权利。 ...

Core Viewpoint - The successful administration of the first patient in the Phase I clinical trial of IMC-003/IMM72 marks a significant milestone for the company and lays a solid foundation for subsequent clinical trials [1] Group 1: Clinical Trial Progress - The first patient has been successfully dosed in the Phase I clinical trial of IMC-003/IMM72 [1] - This event signifies a major milestone in the clinical research of IMC-003/IMM72 [1] Group 2: Product Information - IMC-003/IMM72 is a next-generation ActRIIA-Fc fusion protein developed through genetic modification, featuring higher activity and quality [1] - The company holds global intellectual property rights as well as development and commercialization rights for IMC-003/IMM72 [1]

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 IMC-003/IMM72 第一期臨床試驗的首名患者給藥 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 – 2 – IMC-003/IMM72為通過基因改造的新一代啟動素受體IIA-Fc型(ActRIIA-Fc)融合 蛋白，具有更高的活性及品質。本集團擁有IMC-003/IMM72的全球知識產權以 及開發及商業化權利。 – 1 – 根據香港聯合交易所有限公司證券上市規則第18A.05條的警示聲明：本公司無 法保證能夠成功開發或最終上市銷售IMC-003/IMM72。本公司股東及潛在投資 者在買賣本公司股份時應謹慎行事。 承董事會命 宜明昂科生物醫藥技術（上海）股份有限公司 董事長兼執行董事 田文志 中國上海，二零二五年八月十八日 於本公告日 ...

格隆汇8月12日丨宜明昂科-B(01541.HK)宣布，本公司将于2025年8月26日（星期二）举行董事会会议， 藉以（其中包括）考虑及批准本公司及其附属公司截至2025年6月30日止六个月的中期业绩及其刊发， 并考虑建议派发中期股息（如有）。 ...

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. （股份代號：1541） 宜明昂科生物醫藥技術（上海）股份有限公司 董事會會議召開日期 宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」）董事（「董事」）會（「董 事會」）謹此宣佈，本公司將於二零二五年八月二十六日（星期二）舉行董事會 會議，藉以（其中包括）考慮及批准本公司及其附屬公司截至二零二五年六月 三十日止六個月的中期業績及其刊發，並考慮建議派發中期股息（如有）。 承董事會命 宜明昂科生物醫藥技術（上海）股份有限公司 董事長兼執行董事 田文志 中國上海，二零二五年八月十二日 於本公告日期，董事會由以下成員組成：(i)執行董事田文志博士、李松先生、關梅女士及 張如亮先生；(ii)非執行董事徐聰博士及付大偉女士；及(iii)獨立非執行董事朱禎平博士、 Kendall ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 宜明昂科生物醫藥技術（上海）股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01541 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 396,277,305 | RMB | | 1 RMB | | 396,277,305 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 396,277,305 | RMB | | 1 RMB | | 396,277,305 | ...

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

宜明昂科-B(01541)发布公告，于IMM2510/AXN-2510获FDA批准于美国展开I期临床试验后，公司已从 Instil收取1000万美元的里程碑付款。截至本公告日期，根据授权及合作协议收取的付款总额已达3000 万美元(包括里程碑付款)，显示公司与Instil之间的持续进展及坚定承诺。 ...

Group 1 - The core point of the article is that Yiming Anke-B (01541) has received FDA approval to initiate Phase I clinical trials for IMM2510/AXN-2510 in the United States, leading to a milestone payment of 10 million USD from Instil [1] - As of the date of the announcement, the total payments received under the authorization and collaboration agreement have reached 30 million USD, including milestone payments, indicating ongoing progress and commitment between the company and Instil [1]